Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism in the presence of thrombophilia: Findings from RE-COVER®, RE-COVER™ II, and RE-MEDY™ - PubMed

Affiliations

• PMID: 27807306
• DOI: 10.1177/1358863X16668588

Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism in the presence of thrombophilia: Findings from RE-COVER®, RE-COVER™ II, and RE-MEDY™

Samuel Z Goldhaber et al. Vasc Med. 2016 Dec.

Abstract

It is unclear whether thrombophilia causes resistance to anticoagulant therapy. Post hoc analyses of data from RE-COVER^®, RE-COVER^™ II, and RE-MEDY^™ were performed to compare dabigatran etexilate with warfarin for the treatment and prevention of venous thromboembolism (VTE) in patients with thrombophilia or antiphospholipid antibody syndrome (APS). There were no significant differences in symptomatic VTE/VTE-related deaths between dabigatran etexilate and warfarin in patients with or without thrombophilia. All bleeding event categories were less frequent with dabigatran etexilate than with warfarin, regardless of whether patients had thrombophilia, no thrombophilia, or were not tested. However, these differences did not reach significance in every group. In patients with APS, there was no significant difference in VTE/VTE-related deaths between the two treatment arms. Rates of bleeding events tended to be lower with dabigatran etexilate than with warfarin, reaching statistical significance for any bleeding event. In conclusion, the efficacy and safety of dabigatran etexilate were not significantly affected by the presence of thrombophilia or APS. ClinicalTrials.gov RECOVER IDENTIFIER NCT00291330; RECOVER II IDENTIFIER NCT00680186; RE-MEDY IDENTIFIER NCT00329238.

Keywords: antiphospholipid antibody syndrome; dabigatran; thrombophilia; venous thromboembolism; warfarin.

Similar articles

• Dabigatran versus Warfarin for Acute Venous Thromboembolism in Elderly or Impaired Renal Function Patients: Pooled Analysis of RE-COVER and RE-COVER II.

  Goldhaber SZ, Schulman S, Eriksson H, Feuring M, Fraessdorf M, Kreuzer J, Schüler E, Schellong S, Kakkar A. Goldhaber SZ, et al. Thromb Haemost. 2017 Nov;117(11):2045-2052. doi: 10.1160/TH17-03-0176. Epub 2017 Oct 4. Thromb Haemost. 2017. PMID: 29202209

• Net clinical benefit of dabigatran vs. warfarin in venous thromboembolism: analyses from RE-COVER^®, RE-COVER™ II, and RE-MEDY™.

  Feuring M, Schulman S, Eriksson H, Kakkar AJ, Schellong S, Hantel S, Schueler E, Kreuzer J, Goldhaber SZ. Feuring M, et al. J Thromb Thrombolysis. 2017 May;43(4):484-489. doi: 10.1007/s11239-017-1479-z. J Thromb Thrombolysis. 2017. PMID: 28210989 Free PMC article.

• Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer.

  Schulman S, Goldhaber SZ, Kearon C, Kakkar AK, Schellong S, Eriksson H, Hantel S, Feuring M, Kreuzer J. Schulman S, et al. Thromb Haemost. 2015 Jul;114(1):150-7. doi: 10.1160/TH14-11-0977. Epub 2015 Mar 5. Thromb Haemost. 2015. PMID: 25739680

• Treatment of venous thromboembolism with dabigatran.

  Schulman S. Schulman S. Curr Opin Pulm Med. 2012 Sep;18(5):410-5. doi: 10.1097/MCP.0b013e32835466eb. Curr Opin Pulm Med. 2012. PMID: 22617811 Review.

Cited by

• Anticoagulation in Italian patients with venous thromboembolism and thrombophilic alterations: findings from START2 register study.

  Margaglione M, Antonucci E, D'Andrea G, Migliaccio L, Ageno W, Bucherini E, Cosmi B, Falanga A, Martini G, Mastroiacovo D, Paparo C, Poli D, Testa S, Palareti G. Margaglione M, et al. Blood Transfus. 2020 Nov;18(6):486-495. doi: 10.2450/2020.0091-20. Epub 2020 Sep 18. Blood Transfus. 2020. PMID: 32955425 Free PMC article.

• 16th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends.

  Cohen H, Cuadrado MJ, Erkan D, Duarte-Garcia A, Isenberg DA, Knight JS, Ortel TL, Rahman A, Salmon JE, Tektonidou MG, Williams DJ, Willis R, Woller SC, Andrade D. Cohen H, et al. Lupus. 2020 Oct;29(12):1571-1593. doi: 10.1177/0961203320950461. Lupus. 2020. PMID: 33100166 Free PMC article. Review.

• Therapy with direct oral anticoagulants for secondary prevention of thromboembolic events in the antiphospholipid syndrome: a systematic review and meta-analysis of randomised trials.

  Adelhelm JBH, Christensen R, Balbi GGM, Voss A. Adelhelm JBH, et al. Lupus Sci Med. 2023 Oct;10(2):e001018. doi: 10.1136/lupus-2023-001018. Lupus Sci Med. 2023. PMID: 37899090 Free PMC article.

• Direct oral anticoagulants vs. vitamin K antagonists in patients with antiphospholipid syndrome: a systematic review and meta-analysis.

  Shah BB, Shankar A, Kumar V, Kumar S, Malik UA, Majeed A, Kumar V, Berkha, Suman, Kumar S, Netha A, Subedi S, Ahmed S. Shah BB, et al. Ann Med Surg (Lond). 2023 May 25;85(7):3574-3582. doi: 10.1097/MS9.0000000000000903. eCollection 2023 Jul. Ann Med Surg (Lond). 2023. PMID: 37427194 Free PMC article.

• Warfarin involvement, in comparison to NOACs, in the development of systemic atherosclerosis.

  Mihaila RG. Mihaila RG. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2022 May;166(2):150-154. doi: 10.5507/bp.2022.008. Epub 2022 Feb 18. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2022. PMID: 35228757 Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Atypon
  • Ovid Technologies, Inc.

• Other Literature Sources

  • scite Smart Citations

• Medical

  • MedlinePlus Health Information

• Miscellaneous

  • NCI CPTAC Assay Portal